Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia
- 6 November 2018
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (21), 2937-2946
- https://doi.org/10.1182/bloodadvances.2018022962
Abstract
Activating MYD88 mutations are present in 95% of Waldenström macroglobulinemia (WM) patients, and trigger NF-κB through BTK and IRAK. The BTK inhibitor ibrutinib is active in MYD88-mutated (MYD88MUT) WM patients, but shows lower activity in MYD88 wild-type (MYD88WT) disease. MYD88WT patients also show shorter overall survival, and increased risk of disease transformation in some series. The genomic basis for these findings remains to be clarified. We performed whole exome and transcriptome sequencing of sorted tumor samples from 18 MYD88WT patients and compared findings with WM patients with MYD88MUT disease. We identified somatic mutations predicted to activate NF-κB (TBL1XR1, PTPN13, MALT1, BCL10, NFKB2, NFKBIB, NFKBIZ, and UDRL1F), impart epigenomic dysregulation (KMT2D, KMT2C, and KDM6A), or impair DNA damage repair (TP53, ATM, and TRRAP). Predicted NF-κB activating mutations were downstream of BTK and IRAK, and many overlapped with somatic mutations found in diffuse large B-cell lymphoma. A distinctive transcriptional profile in MYD88WT WM was identified, although most differentially expressed genes overlapped with MYD88MUT WM consistent with the many clinical and morphological characteristics that are shared by these WM subgroups. Overall survival was adversely affected by mutations in DNA damage response in MYD88WT WM patients. The findings depict genomic and transcriptional events associated with MYD88WT WM and provide mechanistic insights for disease transformation, decreased ibrutinib activity, and novel drug approaches for this population.Keywords
This publication has 40 references indexed in Scilit:
- Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemiaBlood, 2014
- Whole Exome Sequencing Identifies Novel Recurrently Mutated Genes in Patients with Splenic Marginal Zone LymphomaPLOS ONE, 2013
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaBlood, 2013
- MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionBlood, 2013
- Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomasProceedings of the National Academy of Sciences of the United States of America, 2013
- MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In VivoCancer Cell, 2012
- Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System LymphomasClinical Cancer Research, 2012
- Advances in Targeting IKK and IKK-Related Kinases for Cancer TherapyClinical Cancer Research, 2008
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaCancer Cell, 2007
- Direct Assessment of CXCR4 Mutant Conformations Reveals Complex Link between Receptor Structure and Gαi ActivationPublished by Elsevier BV ,2007